49 TWENTYFOURSEVENBIOPHARMA Issue 3 / October 2025 mitigate risk, and improve long-term process reliability. This data/model driven scientific approach may appear counter intuitive in a field where speed and trials and error approaches have dominated for years. However, recent advances in early-phase tools and capabilities now make it possible to take a more insightful yet pragmatic approach to drug development, enabling faster progress by avoiding challenges such as poorly developed or convoluted processes and suboptimal solid-state selection. Early-phase decisions are no longer isolated tasks; they are interdependent steps that shape the efficiency and success of later development. Lonza’s tools and expertise empower biotech and pharmaceutical companies to adopt a “right-first-time” mindset, ensuring that every decision from solid form selection to scale-up is informed, strategic, and resilient. As the complexity of small molecules continues to grow, this integrated approach provides a competitive advantage, supporting faster access to life-saving therapies while optimizing costs and timelines. If you would like to learn more, join Francois Ricard’s presentation on Smarter Molecule Development: AIDriven Tools and Model-Based Approaches in EarlyPhase on Wednesday, October 29, 2025, from 2:30– 2:55 PM (CET) in Hall 4.1 - 4.1L8, Manufacturing 5.0, or stop by our booth 5.1B76 to connect directly with our experts. LONZA FRANCOIS RICARD Executive Director, R&D Lonza Advanced Synthesis
RkJQdWJsaXNoZXIy MjY2OTA4MA==